These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 2668784)

  • 1. A placebo-controlled, randomized, double-masked, variable dosage, clinical trial of azathioprine with and without methylprednisolone in multiple sclerosis.
    Ellison GW; Myers LW; Mickey MR; Graves MC; Tourtellotte WW; Syndulko K; Holevoet-Howson MI; Lerner CD; Frane MV; Pettler-Jennings P
    Neurology; 1989 Aug; 39(8):1018-26. PubMed ID: 2668784
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mitoxantrone: a review of its use in multiple sclerosis.
    Scott LJ; Figgitt DP
    CNS Drugs; 2004; 18(6):379-96. PubMed ID: 15089110
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Double-blind, placebo-controlled, randomized, crossover trial of high-dose methylprednisolone in patients with chronic progressive form of multiple sclerosis.
    Cazzato G; Mesiano T; Antonello R; Monti F; Carraro N; Torre P; Bosco A; Cargnelutti D
    Eur Neurol; 1995; 35(4):193-8. PubMed ID: 7671978
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Double-masked trial of azathioprine in multiple sclerosis. British and Dutch Multiple Sclerosis Azathioprine Trial Group.
    Lancet; 1988 Jul; 2(8604):179-83. PubMed ID: 2899660
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cyclosporine versus azathioprine in the long-term treatment of multiple sclerosis--results of the German multicenter study.
    Kappos L; Patzold U; Dommasch D; Poser S; Haas J; Krauseneck P; Malin JP; Fierz W; Graffenried BU; Gugerli US
    Ann Neurol; 1988 Jan; 23(1):56-63. PubMed ID: 3278672
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical experience with azathioprine: the pros.
    Ellison GW; Myers LW; Mickey MR; Graves MC; Tourtellotte WW; Nuwer MR
    Neurology; 1988 Jul; 38(7 Suppl 2):20-3. PubMed ID: 3290709
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Methylprednisolone in combination with interferon beta-1a for relapsing-remitting multiple sclerosis (MECOMBIN study): a multicentre, double-blind, randomised, placebo-controlled, parallel-group trial.
    Ravnborg M; Sørensen PS; Andersson M; Celius EG; Jongen PJ; Elovaara I; Bartholomé E; Constantinescu CS; Beer K; Garde E; Sperling B
    Lancet Neurol; 2010 Jul; 9(7):672-80. PubMed ID: 20542736
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Azathioprine in rheumatoid arthritis: double-blind study of full versus half doses versus placebo.
    Woodland J; Chaput de Saintonge DM; Evans SJ; Sharman VL; Currey HL
    Ann Rheum Dis; 1981 Aug; 40(4):355-9. PubMed ID: 7020612
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Double blind controlled randomized study on azathioprine efficacy in multiple sclerosis. Preliminary results.
    Milanese C; La Mantia L; Salmaggi A; Campi A; Bortolami C; Tajoli L; Nespolo A; Corridori F
    Ital J Neurol Sci; 1988 Feb; 9(1):53-7. PubMed ID: 3281916
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evoked potentials predict the clinical changes in a multiple sclerosis drug study.
    Nuwer MR; Packwood JW; Myers LW; Ellison GW
    Neurology; 1987 Nov; 37(11):1754-61. PubMed ID: 3313101
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Double blind placebo controlled trial of pulse treatment with methylprednisolone combined with disease modifying drugs in rheumatoid arthritis.
    Hansen TM; Kryger P; Elling H; Haar D; Kreutzfeldt M; Ingeman-Nielsen MW; Olsson AT; Pedersen C; Rahbek A; Tvede N
    BMJ; 1990 Aug; 301(6746):268-70. PubMed ID: 2202458
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Methylprednisolone in multiple sclerosis: a comparison of oral with intravenous therapy at equivalent high dose.
    Alam SM; Kyriakides T; Lawden M; Newman PK
    J Neurol Neurosurg Psychiatry; 1993 Nov; 56(11):1219-20. PubMed ID: 8229035
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Management of worsening multiple sclerosis with mitoxantrone: a review.
    Fox EJ
    Clin Ther; 2006 Apr; 28(4):461-74. PubMed ID: 16750460
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Randomised trial of oral and intravenous methylprednisolone in acute relapses of multiple sclerosis.
    Barnes D; Hughes RA; Morris RW; Wade-Jones O; Brown P; Britton T; Francis DA; Perkin GD; Rudge P; Swash M; Katifi H; Farmer S; Frankel J
    Lancet; 1997 Mar; 349(9056):902-6. PubMed ID: 9093250
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A double-blind controlled trial of high dose methylprednisolone in patients with multiple sclerosis: 1. Clinical effects.
    Milligan NM; Newcombe R; Compston DA
    J Neurol Neurosurg Psychiatry; 1987 May; 50(5):511-6. PubMed ID: 3295122
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High-dose intravenous methylprednisolone in the treatment of multiple sclerosis: clinical-immunologic correlations.
    Durelli L; Cocito D; Riccio A; Barile C; Bergamasco B; Baggio GF; Perla F; Delsedime M; Gusmaroli G; Bergamini L
    Neurology; 1986 Feb; 36(2):238-43. PubMed ID: 3511404
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A randomized clinical trial of oral versus intravenous methylprednisolone for relapse of MS.
    Ramo-Tello C; Grau-López L; Tintoré M; Rovira A; Ramió i Torrenta L; Brieva L; Cano A; Carmona O; Saiz A; Torres F; Giner P; Nos C; Massuet A; Montalbán X; Martínez-Cáceres E; Costa J
    Mult Scler; 2014 May; 20(6):717-25. PubMed ID: 24144876
    [TBL] [Abstract][Full Text] [Related]  

  • 18. T-cell subsets in the cerebrospinal fluid and peripheral blood of multiple sclerosis patients treated with high-dose intravenous methylprednisolone.
    Frequin ST; Lamers KJ; Borm GF; Barkhof F; Jongen PJ; Hommes OR
    Acta Neurol Scand; 1993 Aug; 88(2):80-6. PubMed ID: 8213063
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Double-blind, randomized, placebo-controlled study of oral, high-dose methylprednisolone in attacks of MS.
    Sellebjerg F; Frederiksen JL; Nielsen PM; Olesen J
    Neurology; 1998 Aug; 51(2):529-34. PubMed ID: 9710030
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Cannabinoid Use in Progressive Inflammatory brain Disease (CUPID) trial: a randomised double-blind placebo-controlled parallel-group multicentre trial and economic evaluation of cannabinoids to slow progression in multiple sclerosis.
    Ball S; Vickery J; Hobart J; Wright D; Green C; Shearer J; Nunn A; Cano MG; MacManus D; Miller D; Mallik S; Zajicek J
    Health Technol Assess; 2015 Feb; 19(12):vii-viii, xxv-xxxi, 1-187. PubMed ID: 25676540
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.